{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T19:26:40Z","timestamp":1783970800699,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T00:00:00Z","timestamp":1585612800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T00:00:00Z","timestamp":1585612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Kyowa Kirin"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s12325-019-01174-3","type":"journal-article","created":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T18:04:20Z","timestamp":1585677860000},"page":"38-46","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Paediatric Metabolic Bone Disease: A Lifetime Ahead"],"prefix":"10.1007","volume":"37","author":[{"given":"Carlos","family":"G\u00f3mez-Alonso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,31]]},"reference":[{"key":"1174_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1159\/000380990","volume":"28","author":"J Allgrove","year":"2015","unstructured":"Allgrove J. Physiology of calcium, phosphate, magnesium and vitamin D. Endocr Dev. 2015;28:7\u201332.","journal-title":"Endocr Dev"},{"key":"1174_CR2","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1056\/NEJMra070553","volume":"357","author":"MF Holick","year":"2007","unstructured":"Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266\u201381.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"1174_CR3","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.2215\/CJN.05910809","volume":"5","author":"M Peacock","year":"2010","unstructured":"Peacock M. Calcium metabolism in health and disease. Clin J Am Soc Nephrol. 2010;5(Suppl 1):S23\u201330.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1174_CR4","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1056\/NEJMra053077","volume":"354","author":"E Seeman","year":"2006","unstructured":"Seeman E, Delmas PD. Bone quality\u2014the material and structural basis of bone strength and fragility. N Engl J Med. 2006;354:2250\u201361.","journal-title":"N Engl J Med"},{"key":"1174_CR5","doi-asserted-by":"publisher","first-page":"25103","DOI":"10.1074\/jbc.R109.041087","volume":"285","author":"LJ Raggatt","year":"2010","unstructured":"Raggatt LJ, Partridge NC. Cellular and molecular mechanisms of bone remodeling. J Biol Chem. 2010;285:25103\u20138.","journal-title":"J Biol Chem"},{"key":"1174_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/BF03347390","volume":"30","author":"V Camozzi","year":"2007","unstructured":"Camozzi V, Tossi A, Simoni E, et al. Role of biochemical markers of bone remodeling in clinical practice. J Endocrinol Invest. 2007;30:13\u20137.","journal-title":"J Endocrinol Invest"},{"key":"1174_CR7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","volume":"22","author":"S Vasikaran","year":"2011","unstructured":"Vasikaran S, Eastell R, Bruyere O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22:391\u2013420.","journal-title":"Osteoporos Int"},{"key":"1174_CR8","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1515\/jpem-2014-0525","volume":"29","author":"SA Bowden","year":"2016","unstructured":"Bowden SA, Akusoba CI, Hayes JR, Mahan JD. Biochemical markers of bone turnover in children with clinical bone fragility. J Pediatr Endocrinol Metab. 2016;29:715\u201322.","journal-title":"J Pediatr Endocrinol Metab"},{"key":"1174_CR9","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1210\/jc.2010-2546","volume":"96","author":"AM Boyce","year":"2011","unstructured":"Boyce AM, Gafni RI. Approach to the child with fractures. J Clin Endocrinol Metab. 2011;96:1943\u201352.","journal-title":"J Clin Endocrinol Metab"},{"key":"1174_CR10","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.3390\/ijms19051407","volume":"19","author":"L Arseni","year":"2018","unstructured":"Arseni L, Lombardi A, Orioli D. From structure to phenotype: impact of collagen alterations on human health. Int J Mol Sci. 2018;19:1407.","journal-title":"Int J Mol Sci"},{"key":"1174_CR11","doi-asserted-by":"publisher","first-page":"17052","DOI":"10.1038\/nrdp.2017.52","volume":"3","author":"JC Marini","year":"2017","unstructured":"Marini JC, Forlino A, Bachinger HP, et al. Osteogenesis imperfecta. Nat Rev Dis Primers. 2017;3:17052.","journal-title":"Nat Rev Dis Primers"},{"key":"1174_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/jbmr.2920","volume":"32","author":"L Folkestad","year":"2017","unstructured":"Folkestad L, Hald JD, Ersboll AK, et al. Fracture rates and fracture sites in patients with osteogenesis imperfecta: a nationwide register-based cohort study. J Bone Miner Res. 2017;32:125\u201334.","journal-title":"J Bone Miner Res"},{"key":"1174_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.afos.2018.05.002","volume":"4","author":"VH Nguyen","year":"2018","unstructured":"Nguyen VH. School-based exercise interventions effectively increase bone mineralization in children and adolescents. Osteoporos Sarcopenia. 2018;4:39\u201346.","journal-title":"Osteoporos Sarcopenia"},{"key":"1174_CR14","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1002\/jbmr.2895","volume":"31","author":"L Folkestad","year":"2016","unstructured":"Folkestad L, Hald JD, Canudas-Romo V, et al. Mortality and causes of death in patients with osteogenesis imperfecta: a register-based nationwide cohort study. J Bone Miner Res. 2016;31:2159\u201366.","journal-title":"J Bone Miner Res"},{"key":"1174_CR15","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJM199810013391402","volume":"339","author":"FH Glorieux","year":"1998","unstructured":"Glorieux FH, Bishop NJ, Plotkin H, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339:947\u201352.","journal-title":"N Engl J Med"},{"key":"1174_CR16","first-page":"24","volume":"16","author":"H Hoyer-Kuhn","year":"2016","unstructured":"Hoyer-Kuhn H, Franklin J, Allo G, et al. Safety and efficacy of denosumab in children with osteogenesis imperfect\u2014a first prospective trial. J Musculoskelet Neuronal Interact. 2016;16:24\u201332.","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"1174_CR17","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/jbmr.2410","volume":"30","author":"JD Hald","year":"2015","unstructured":"Hald JD, Evangelou E, Langdahl BL, Ralston SH. Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials. J Bone Miner Res. 2015;30:929\u201333.","journal-title":"J Bone Miner Res"},{"key":"1174_CR18","doi-asserted-by":"publisher","first-page":"e894","DOI":"10.1097\/MJT.0000000000000236","volume":"23","author":"CG Shi","year":"2016","unstructured":"Shi CG, Zhang Y, Yuan W. Efficacy of bisphosphonates on bone mineral density and fracture rate in patients with osteogenesis imperfecta: a systematic review and meta-analysis. Am J Ther. 2016;23:e894\u2013904.","journal-title":"Am J Ther"},{"key":"1174_CR19","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.5037\/jomr.2013.4401","volume":"4","author":"AA Hennedige","year":"2013","unstructured":"Hennedige AA, Jayasinghe J, Khajeh J, Macfarlane TV. Systematic review on the incidence of bisphosphonate related osteonecrosis of the jaw in children diagnosed with osteogenesis imperfecta. J Oral Maxillofac Res. 2013;4:e1.","journal-title":"J Oral Maxillofac Res"},{"key":"1174_CR20","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/nm.3544","volume":"20","author":"I Grafe","year":"2014","unstructured":"Grafe I, Yang T, Alexander S, et al. Excessive transforming growth factor-beta signaling is a common mechanism in osteogenesis imperfecta. Nat Med. 2014;20:670\u20135.","journal-title":"Nat Med"},{"key":"1174_CR21","unstructured":"SESEP Laboratory. The tissue nonspecific alkaline phosphatase gene mutations database. 2019. http:\/\/www.sesep.uvsq.fr\/03_hypo_mutations.php. Accessed 12 Mar 2019."},{"key":"1174_CR22","doi-asserted-by":"publisher","first-page":"9569","DOI":"10.1038\/s41598-019-46004-2","volume":"9","author":"C Garcia-Fontana","year":"2019","unstructured":"Garcia-Fontana C, Villa-Suarez JM, Andujar-Vera F, et al. Epidemiological, clinical and genetic study of hypophosphatasia in a Spanish population: identification of two novel mutations in the Alpl gene. Sci Rep. 2019;9:9569.","journal-title":"Sci Rep"},{"key":"1174_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.bone.2013.01.024","volume":"54","author":"KE Berkseth","year":"2013","unstructured":"Berkseth KE, Tebben PJ, Drake MT, et al. Clinical spectrum of hypophosphatasia diagnosed in adults. Bone. 2013;54:21\u20137.","journal-title":"Bone"},{"key":"1174_CR24","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ymgme.2016.06.010","volume":"119","author":"D Phillips","year":"2016","unstructured":"Phillips D, Case LE, Griffin D, et al. Physical therapy management of infants and children with hypophosphatasia. Mol Genet Metab. 2016;119:14\u20139.","journal-title":"Mol Genet Metab"},{"key":"1174_CR25","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.bone.2015.02.022","volume":"75","author":"MP Whyte","year":"2015","unstructured":"Whyte MP, Zhang F, Wenkert D, et al. Hypophosphatasia: validation and expansion of the clinical nosology for children from 25\u00a0years experience with 173 pediatric patients. Bone. 2015;75:229\u201339.","journal-title":"Bone"},{"key":"1174_CR26","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s12891-016-1191-8","volume":"17","author":"T Bhattacharyya","year":"2016","unstructured":"Bhattacharyya T, Jha S, Wang H, Kastner DL, Remmers EF. Hypophosphatasia and the risk of atypical femur fractures: a case-control study. BMC Musculoskelet Disord. 2016;17:332.","journal-title":"BMC Musculoskelet Disord"},{"key":"1174_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/jbm4.10064","volume":"3","author":"P Peris","year":"2019","unstructured":"Peris P, Gonz\u00e1lez-Roca E, Rodr\u00edguez-Garc\u00eda SC, et al. Incidence of mutations in the ALPL, GGPS1, and CYP1A1 genes in patients with atypical femoral fractures. JBMR Plus. 2019;3:29\u201336.","journal-title":"JBMR Plus"},{"key":"1174_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.medcli.2017.06.040","volume":"150","author":"N Guanabens","year":"2018","unstructured":"Guanabens N, Blanch J, Martinez-Diaz-Guerra G, Munoz Torres M. Identification of hypophosphatasia in a clinical setting: clinical manifestations and diagnostic recommendations in adult patients. Med Clin (Barc). 2018;150:75\u20139.","journal-title":"Med Clin (Barc)"},{"key":"1174_CR29","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nrendo.2016.14","volume":"12","author":"MP Whyte","year":"2016","unstructured":"Whyte MP. Hypophosphatasia\u2014aetiology, nosology, pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2016;12:233\u201346.","journal-title":"Nat Rev Endocrinol"},{"key":"1174_CR30","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1056\/NEJMoa1106173","volume":"366","author":"MP Whyte","year":"2012","unstructured":"Whyte MP, Greenberg CR, Salman NJ, et al. Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med. 2012;366:904\u201313.","journal-title":"N Engl J Med"},{"key":"1174_CR31","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.bone.2018.12.011","volume":"121","author":"PS Kishnani","year":"2019","unstructured":"Kishnani PS, Rockman-Greenberg C, Rauch F, et al. Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia. Bone. 2019;121:149\u201362.","journal-title":"Bone"},{"key":"1174_CR32","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000491042","volume":"51","author":"Y Hakami","year":"2019","unstructured":"Hakami Y, Khan A. Hypoparathyroidism. Front Horm Res. 2019;51:109\u201326.","journal-title":"Front Horm Res"},{"key":"1174_CR33","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1159\/000380997","volume":"28","author":"NJ Shaw","year":"2015","unstructured":"Shaw NJ. A practical approach to hypocalcaemia in children. Endocr Dev. 2015;28:84\u2013100.","journal-title":"Endocr Dev"},{"key":"1174_CR34","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.jocn.2014.11.020","volume":"22","author":"TH Eom","year":"2015","unstructured":"Eom TH, Kim YH, Kim JM. Recurrent seizures, mental retardation and extensive brain calcinosis related to delayed diagnosis of hypoparathyroidism in an adolescent boy. J Clin Neurosci. 2015;22:894\u20136.","journal-title":"J Clin Neurosci"},{"key":"1174_CR35","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1002\/jbmr.483","volume":"26","author":"JP Bilezikian","year":"2011","unstructured":"Bilezikian JP, Khan A, Potts JT Jr, et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res. 2011;26:2317\u201337.","journal-title":"J Bone Miner Res"},{"key":"1174_CR36","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1210\/jc.2015-3910","volume":"101","author":"JP Bilezikian","year":"2016","unstructured":"Bilezikian JP, Brandi ML, Cusano NE, et al. Management of hypoparathyroidism: present and future. J Clin Endocrinol Metab. 2016;101:2313\u201324.","journal-title":"J Clin Endocrinol Metab"},{"key":"1174_CR37","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1210\/jc.2012-1808","volume":"97","author":"DM Mitchell","year":"2012","unstructured":"Mitchell DM, Regan S, Cooley MR, et al. Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab. 2012;97:4507\u201314.","journal-title":"J Clin Endocrinol Metab"},{"key":"1174_CR38","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1359\/jbmr.080803","volume":"23","author":"MR Rubin","year":"2008","unstructured":"Rubin MR, Dempster DW, Zhou H, et al. Dynamic and structural properties of the skeleton in hypoparathyroidism. J Bone Miner Res. 2008;23:2018\u201324.","journal-title":"J Bone Miner Res"},{"key":"1174_CR39","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/jbmr.2609","volume":"31","author":"NE Cusano","year":"2016","unstructured":"Cusano NE, Nishiyama KK, Zhang C, et al. Noninvasive assessment of skeletal microstructure and estimated bone strength in hypoparathyroidism. J Bone Miner Res. 2016;31:308\u201316.","journal-title":"J Bone Miner Res"},{"key":"1174_CR40","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1080\/14740338.2017.1311322","volume":"16","author":"G Marcucci","year":"2017","unstructured":"Marcucci G, Della Pepa G, Brandi ML. Drug safety evaluation of parathyroid hormone for hypocalcemia in patients with hypoparathyroidism. Expert Opin Drug Saf. 2017;16:617\u201325.","journal-title":"Expert Opin Drug Saf"},{"issue":"391\u201399","key":"1174_CR41","first-page":"e1","volume":"203","author":"KK Winer","year":"2018","unstructured":"Winer KK, Kelly A, Johns A, et al. Long-term parathyroid hormone 1\u201334 replacement therapy in children with hypoparathyroidism. J Pediatr. 2018;203(391\u201399):e1.","journal-title":"J Pediatr"},{"key":"1174_CR42","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1210\/jc.2017-01471","volume":"103","author":"TJ Vokes","year":"2018","unstructured":"Vokes TJ, Mannstadt M, Levine MA, et al. Recombinant human parathyroid hormone effect on health-related quality of life in adults with chronic hypoparathyroidism. J Clin Endocrinol Metab. 2018;103:722\u201331.","journal-title":"J Clin Endocrinol Metab"},{"key":"1174_CR43","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.340","volume":"26","author":"TO Carpenter","year":"2011","unstructured":"Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician\u2019s guide to X-linked hypophosphatemia. J Bone Miner Res. 2011;26:1381\u20138.","journal-title":"J Bone Miner Res"},{"key":"1174_CR44","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s10545-018-0147-6","volume":"41","author":"D Chesher","year":"2018","unstructured":"Chesher D, Oddy M, Darbar U, et al. Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations. J Inherit Metab Dis. 2018;41:865\u201376.","journal-title":"J Inherit Metab Dis"},{"key":"1174_CR45","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1210\/js.2018-00365","volume":"3","author":"A Skrinar","year":"2019","unstructured":"Skrinar A, Dvorak-Ewell M, Evins A, et al. The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey. J Endocr Soc. 2019;3:1321\u201334.","journal-title":"J Endocr Soc"},{"key":"1174_CR46","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1210\/JC.2015-2199","volume":"100","author":"J Connor","year":"2015","unstructured":"Connor J, Olear EA, Insogna KL, et al. Conventional therapy in adults with X-linked hypophosphatemia: effects on enthesopathy and dental disease. J Clin Endocrinol Metab. 2015;100:3625\u201332.","journal-title":"J Clin Endocrinol Metab"},{"key":"1174_CR47","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1210\/jc.2014-2017","volume":"99","author":"TO Carpenter","year":"2014","unstructured":"Carpenter TO, Olear EA, Zhang JH, et al. Effect of paricalcitol on circulating parathyroid hormone in X-linked hypophosphatemia: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2014;99:3103\u201311.","journal-title":"J Clin Endocrinol Metab"},{"key":"1174_CR48","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/jbmr.3475","volume":"33","author":"KL Insogna","year":"2018","unstructured":"Insogna KL, Briot K, Imel EA, et al. A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res. 2018;33:1383\u201393.","journal-title":"J Bone Miner Res"},{"key":"1174_CR49","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","volume":"7","author":"MP Whyte","year":"2019","unstructured":"Whyte MP, Carpenter TO, Gottesman GS, et al. Efficacy and safety of burosumab in children aged 1\u20134\u00a0years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. Lancet Diabetes Endocrinol. 2019;7:189\u201399.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1174_CR50","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","volume":"105","author":"AA Portale","year":"2019","unstructured":"Portale AA, Carpenter TO, Brandi ML, et al. Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period. Calcif Tissue Int. 2019;105:271\u201384.","journal-title":"Calcif Tissue Int"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01174-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-01174-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01174-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T23:33:40Z","timestamp":1617147220000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-01174-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,31]]},"references-count":50,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["1174"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-01174-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,31]]},"assertion":[{"value":"11 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}